When was the last time you achieved the impossible? If that thought feels overwhelming, you might want to pause here, but if it sparks excitement…read on
In 2015, we pioneered a “moneyball for biotech” approach, pooling projects and promising early-stage research from academia together under one financial umbrella to reduce risk and unleash innovation. This model allows science and small teams of experts to lead the way. We build bridges to groundbreaking advancements in rare disease, and develop life-changing medicines for patients with unmet needs as fast as humanly possible.
Together we define white space, push boundaries and empower people to solve problems. If you're someone who defies convention, join us and work alongside some of the most respected minds in the industry. Together, we'll ask "why not?" and help reengineer the future of biopharma.
Eidos Therapeutics, an affiliate within BridgeBio Pharma, is a commercial-stage biopharmaceutical company focused on Transthyretin Amyloid Cardiomyopathy (ATTR-CM).
BridgeBio seeks a Sr. Director/Executive Director, Analytical Development to lead our analytical development (AD) and commercial quality control (QC) groups supporting our late-stage novel small molecule development programs. While this position is responsible for authoring and revising analytical development (AD) sections of regulatory submissions (e.g., IND, IMPD, NDA, MAA, etc.), input on CMC regulatory strategy for both drug substance (DS) and drug product (DP) across the BridgeBio cardiorenal small molecule portfolio is also expected. Therefore, a comprehensive understanding of relevant ICH guidelines and health authority expectations for small molecule new chemical entities (NCEs) is required.
As BridgeBio is a virtual organization, external CDMO management experience is a plus. Additional responsibilities include oversight of late development/launch preparation activities, including analytical method transfers, method development, phase-appropriate validation for both DS and DP and the review of analytical packages for the release of clinical/commercial supplies. The position requires close collaboration with drug substance and formulation scientists and Quality Assurance. Working knowledge of GMPs, various small molecule analytical techniques, including HPLC, GC, GC/MS, LC/MS, ICP, dissolution (discriminating and USP), UV, IR, NMR, XRPD, Karl Fischer titration, DSC, and TGA is required—excellent communication skills (both verbal and written) a must.
This is a U.S.-based remote role that will require monthly visits for the first six months of onboarding and then scheduled visits to our San Francisco Office as needed.
We have high expectations for our team members. We make sure those working hard for patients are rewarded and cared for in return.
Health & Wellbeing:
Skill Development & Career Paths:
BridgeBio is a biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. We bridge the gap between remarkable advancements in genetic science in academic institutions and the delivery of meaningful medicines to patients. Founded in 2015, the company has built a portfolio of 20+ drug development programs ranging from preclinical to late-stage development in multiple therapeutic areas including genetic dermatology, precision oncology, cardiology, endocrinology, neurology, pulmonology, and renal disease, with two approved drugs. Our focus on scientific excellence and rapid execution aim to translate today’s discoveries into tomorrow’s medicines. We have U.S. offices in San Francisco, Palo Alto, and Raleigh, with small satellites in other parts of the country. We also have international offices in Montreal, Canada, and Zurich, Switzerland, and are expanding across Europe. To learn more about our story and company culture, visit us at https://bridgebio.com
Understand the required skills and qualifications, anticipate the questions you may be asked, and study well-prepared answers using our sample responses.
Executive Director Q&A's